西达本胺治疗21例外周T细胞淋巴瘤的临床分析

尤莎莎; 钱申贤; 黄细莲; 刘利蓉; 施鹏飞; 陈况

doi:10.13201/j.issn.1004-2806.2020.11.011

西达本胺治疗21例外周T细胞淋巴瘤的临床分析

- 1. 浙江中医药大学第四临床医学院(杭州, 310053);
- 2. 浙江大学医学院附属杭州市第一人民医院血液科

详细信息

通讯作者: 钱申贤,E-mail:sxqian@hotmail.com

中图分类号: R733.4

收稿日期: 2020-06-15

Clinical analysis of 21 patients with peripheral T-cell lymphoma treated by chidamide

- 1 Fourth Clinical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China;
- 2 Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

More Information

Corresponding author: QIAN Shen-xian, E-mail: sxqian@hotmail.com

Received Date: 15 June 2020

摘要

摘要: 目的:分析西达本胺治疗外周T细胞淋巴瘤（PTCL）的疗效及安全性,探讨西达本胺联合治疗的新组合方案。方法:回顾性分析2009-11-2020-05于我院诊断并应用西达本胺治疗的21例PTCL患者的临床资料,分析其疗效及不良反应。结果:21例患者中完全缓解1例,部分缓解9例,疾病稳定1例,疾病进展10例,总有效率52.4%。中位随访时间9个月,中位无进展生存期140 d,6个月无进展生存率58.8%,1年无进展生存率52.9%。4例接受西达本胺单药治疗的患者,总有效率为50.0%;17例接受西达本胺联合治疗的患者,总有效率为52.9%。大多数不良反应为1～2级,3～4级不良反应多见血小板减少及中性粒细胞减少。结论:西达本胺治疗PTCL安全有效,且联合方案（联合化疗或去甲基化药物）可能是为部分难治或复发PTCL患者带来更大获益的一种新的治疗选择。
- 西达本胺 /
- 外周T细胞淋巴瘤 /
- 化疗 /
- 阿扎胞苷
Abstract: Objective:To evaluate the safety and effects of chidamide in the treatment of peripheral T-cell lymphoma（PTCL）,and to explore new combined treatment.Method:The clinical data of 21 PTCL patients treated with chidamide at our institution from November 2009 to May 2020 were analyzed retrospectively.The responses and adverse events were evaluated.Result:Among 21 patients,1 case achieved complete remission,9 cases achieved partial remission,1 case being with stable disease and 10 cases being with progressive disease.The overall response rate was 52.4%.The median follow-up time was 9 months and the median progression-free survival（PFS） was 140 days.The 6-month PFS and the 1-year PFS were 58.8% and 52.9%,respectively.For 4 patients receiving chidamide monotherapy,the overall response rate was 50.0%.For 17 patients receiving chidamide combination therapy,the overall response rate was 52.9%.Most adverse events were grade 1 to 2.Adverse events of grade 3 or higher mostly were thrombocytopenia and neutropenia.Conclusion:This real-world study demonstrates that chidamide has a favorable efficacy and an acceptable safety profile for patients with refractory or relapsed PTCL.Chidamide combined with chemotherapy or demethylation agents may be a new treatment option for patients with refractory or relapsed PTCL.
- chidamide /
- peripheral T-cell lymphoma /
- chemotherapy /
- azacitidine

HTML全文

参考文献(13)

[1]	黄晓军.实用造血干细胞移植[M].北京:人民卫生出版社,2014:77-78.
[2]	Xu LP,Huang XJ.Current status and development of hematopoietic stem cell transplantation in China:a report from Chinese Hematopoietic Stem Cell Transplantation Register Group[J].Chin Med J (Engl),2011,124:2548-2555.
[3]	Ljungman P,Bregni M,Brune M,et al.Allogeneic and autologous transplantation for haematological diseases,solid tumours and immune disorders:current practice in Europe 2009[J].Bone Marrow Transplant,2010,45:219-234.
[4]	郑晓丽,韩冬梅,丁丽,等.单倍体相合造血干细胞移植联合脐带间充质干细胞输注治疗重型再生障碍性贫血并活动性感染的疗效及安全性分析[J].临床血液学杂志,2019,32(5):367-370.
[5]	罗荣牡,张晓妹,杜振兰,等.单倍体造血干细胞移植治疗儿童获得性再生障碍性贫血单中心回顾性分析[J].中华儿科杂志,2018,56(7):529-533.
[6]	Barba P,Pinana JL,Fernández-Avilés F,et al.Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation:a study of 455 patients[J].Biol Blood Marrow Transplant,2011,17:1653-1661.
[7]	赵珺,任汉云,邱志祥,等.移植前及预处理期间肝功能异常对异基因造血干细胞移植效果的影响[J].中华内科杂志,2014,53(2):99-103.
[8]	Faraci M,Bertaina A,Luksch R,et al.Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children:a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group[J].Biol Blood Marrow Transplant,2019,25:313-320.
[9]	Sung-Nam Lim,Sun-Hye Ko,Seonyang Park.Prophylactic Prostaglandin E1 Prevent Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease of the Liver after Allogeneic Hematopoietic Stem Cell Transplantation[J].Elsevier Inc,2020,26:139-139.
[10]	ElGohary G,El Fakih R,de Latour R,et al.Haploidentical hematopoietic stem cell transplantation in aplastic anemia:a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT)[J].Bone Marrow Transplant,2020;10.1038/s41409-020-0897-2.doi:10.1038/s41409-020-0897-2[published online ahead of print,2020 Apr 28].
[11]	王栋,张帆,范晓辉,等.造血干细胞移植后早期细菌感染的临床分析[J].临床血液学杂志,2019,32(5):348-352.
[12]	郭智,陈惠仁,杨凯,等.单倍型异基因造血干细胞移植后患者肺部真菌感染的临床研究[J].中华医院感染学杂志,2015,25(13):2999-3001.[13] Yoshida N,Kojima S.Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children[J].Curr Oncol Rep,2018,20:67.
[14]	Arndt C,Beck JF,Gruhn B.A pediatric prognostic score for patients undergoing allogeneic hematopoietic stem cell transplantation[J].Eur J Haematol,2014,93:509-515.